Sara Rogers, PharmD, BCPS
Director, Clinical Affairs, American Society of Pharmacovigilance
Senior Director, Global Clinical Safety and Pharmacovigilance, Global R&D, CSL Behring
Kristin Wiisanen Weitzel, PharmD, FAPhA,
Clinical Professor, Associate Director, University of Florida Health Precision Medicine Program.
Danielle Harris PharmD, BCPS
Deputy Director,Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA)
Anthony P. Morreale, PharmD, MBA, BCPS,
Associate Chief Consultant, Clinical Pharmacy and Policy, Department of Veterans Affairs Pharmacy Benefits Management.
Tatjana Ajhler Đuretek
Head of Medical Affairs and Pharmacovigilance, EU QPPV, Belupo
Dan Hertz, PharmD, PhD
Assistant Professor, Department of Clinical Pharmacy, University of Michigan College of Pharmacy
Regulatory Affairs and Drug Safety Specialist (LRP-PV), Grünenthal Denmark ApS
Recommended Global Pharmaceutical Sciences Webinars & Conferences
- About Conference
- Session and Tracks
- Market Analysis
- Abstract Submission Criteria and Eligibility
- Participation Options and Benefits
With the grand success of Pharmacovigilance (GPCTS-2023) Series of Conferences in UK, USA in consecutive years over the last several years which met with great achievement in Business Conferencing. It’s glad to announce 16th Global Pharmacovigilance & clinical Trials Summit (GPCTS-2023) during March 27-28, 2023 Vancouver, Canada with the theme “Present Challenges and Futuristic Scope in Pharmacovigilance and Clinical Trials”. 16th Global Pharmacovigilance & Clinical Trials Summit (GPCTS-2023) emphasizes on how importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors.
The field of Pharmacovigilance is growing day by day and its development is marking high impact in fields of Pharmaceuticals and Medical Sciences (GPCTS-2023). This conference creates a global platform to reach the largest assemblage of participants from various sectors to share their insights and convey recent developments in the field of Medicinal sciences, Health care and Drug Discovery involving Pharmacovigilance studies, (GPCTS-2023) Risk Management and Safety of Drug. This is a true forum where ideas and discussion is driven by the participants and interaction with peers and others leads to fruitful outcomes.
Session and Tracks
Track 1: Pharmacovigilance and Clinical Trials
Pharmacovigilance is the wisdom and conditioning relating to the discovery, assessment, understanding and forestalment of adverse goods or any other drug/ vaccine affiliated problem. All drugs and vaccines suffer rigorous testing for safety and efficacy through clinical trials before they're authorized for use. Still, the clinical trial process involves studying these products in a fairly small number of named individualities for a short period of time. Certain side goods may only crop once these products have been used by a miscellaneous population, including people with other concurrent conditions, and over a long period of time.
Track 2: Pharmacovigilance Practice
Good pharmacovigilance practices (GVP) are a set of measures drawn up to grease the performance of pharmacovigilance in the European Union (EU). GVP apply to marketing authorisation holders, the European Medicines Agency (EMA) and drugs nonsupervisory authorities in EU Member States. They cover drugs authorised centrally via the Agency as well as drugs authorised at public position. Medicines aren't the only products considered under the horizon of pharmacovigilance practice, but also Vaccines, Blood products, Medical bias, and Biological, Herbals, Traditional / reciprocal substances.
Track 3: Clinical Trials Pharmacovigilance
Pharmacovigilance begins with clinical trials that give data on the benefits and pitfalls of a medicine. The end of pharmacovigilance in clinical exploration is to determine if the benefits overweigh the pitfalls; if they do, medicine manufacturers take way to gain blessing to request the new medicine. PV in clinical trials is necessary for healthcare professionals and consumers to modernize the implicit pitfalls of specifics. The medicine company may grease post marketing medicine safety surveillance to observe the product’s safety and effectiveness in the real world as it isn't possible to prognosticate all possible adverse goods of a medicine grounded on pre-approval studies. Multitudinous approaches can be espoused, similar as; medicine registries, robotic reporting systems, electronic health records.
Track 4: Adverse Drug Reactions
We define an adverse drug response as an appreciably dangerous or unpleasant response, performing from an intervention related to the use of a medicinal product, which predicts hazard from future administration and concurrences prevention or specific treatment, or modification of the capsule authority, or retirement of the product. Analogous responses are presently reported by use of WHO's Adverse response language, which will eventually come a subset of the International Bracket of conditions.
Adverse drug responses are classified into six types( with mnemonics) cure related( augmented),non-dose related( crazy), cure related and time related( habitual), time related( Delayed), retirement( End of use), and failure of remedy( Failure). Timing, the pattern of illness, the results of examinations, and challenge can help attribute reason to a suspected adverse drug response.
Track 5: Drug Safety
Medicine safety is the main aspect of medical remedy that can play a major part in deciding which medicine should be given to a case. Also, considering the conception of benefit – threat balance, we set up that medicines with a high threat profile should be avoided unless demanded.
- Ameliorate Medication Safety
- Maintain an active drug mislike list.
- Maintain an active drug list.
- Use motorized croaked order entry for drug orders.
- Induce and transmit electronic conventions for noncontrolled substances
Track 6: Clinical Research and Statistics
As the field of statistics, the theoretical wisdom or formal study of the deducible process, especially the planning and analysis of trials, checks, and experimental studies. (Piantadosi 2005) has developed in the twentieth century clinical exploration has employed statistical styles to give formal account for sources of variability in case’s responses to treatment. The use of statistics allows clinical experimenters to draw reasonable and accurate consequences from collected information and to make sound opinions in the presence of query. Mastery of statistical generalities can help multitudinous crimes and impulses in medical exploration.
Track 7: Clinical Database Management
Clinical data operation (CDM) is the running of information that results from clinical trials. All aspects of processing study information are part of clinical data operation. This includes developing and maintaining software systems, databases, processes, procedures, training, and protocols to support collecting, drawing, and managing subject or trial data. The primary part of clinical data operation is to produce and maintain high quality data from data entry through analysis. Performed rightly, the result of clinical data operation is a dataset that's accurate, secure, dependable, and ready for analysis at the end of a study.
Track 8: Analysis of Data Quality and Management
Data quality analysis is the final step in the data understanding stage in which the quality of data is anatomized in the datasets and implicit failings, crimes, and issues are determined. These needs to be resolved before assaying the data further or starting modelling sweats. Data quality operation provides an environment specific process for perfecting the fitness of data that is used for analysis and decision timber. The thing is to produce perceptivity into the health of that data using colourful processes and technologies on decreasingly bigger and more complex data sets. Sanctification enforces the data standardization rules that are demanded to deliver perceptivity from your data sets. This also establishes data scales and reference data delineations to customize data to fit your unique requirements.
Track 9: Regulatory Affairs
Regulatory Affairs approach integrates technology, analytics, and perceptivity erected from times of experience to help biopharma companies exceed global compliance pretensions, reduce costs and get medicines to request faster. Our immolations gauge the medicine development continuum where our backing with the creation of a nonsupervisory strategy and development plan helps exclude surprises, keep development on track, and insure applicable quality strategy at each step. The nonsupervisory affairs (RA) department of a pharmaceutical company is responsible for carrying blessing for new pharmaceutical products and icing that blessing is maintained for as long as the company wants to keep the product on the request.
Track 10: Pharmaceutical Chemistry
Pharmaceutical chemistry is the study of medicines, and it involves medicine development. This includes medicine discovery, delivery, immersion, metabolism, and more. There are rudiments of biomedical analysis, pharmacology, pharmacokinetics, and pharmacodynamics. At the morning of the 21st century, medicinal (medicinal) chemistry has developed new motes with ever adding structural diversity. Piecemeal from the small synthetic ligands and natural products, pharmaceutical apothecaries concentrate on the development of modified peptides and proteins, natural agents (e.g. monoclonal antibodies), multifunctional molecular complexes and synthetic vaccines.
Track 11: Clinical Pharmacology
Clinical pharmacology is the study of drugs. It has a broad compass, from the discovery of new target molecules, to the effects of drug usage in whole populations. Clinical pharmacists are physicians and scientists who focus on developing and understanding new medicine therapies. Clinical pharmacology encompasses all aspects of the relationship between drugs and humans. It's the only medical specialty in the NHS fastening on the safe, effective and profitable use of drugs. It's a different discipline that both sustains and advances stylish healthcare. The main part of a clinical pharmacist in this discipline is to assess the quality and felicity of clinical trials data for addition in the overall analysis, in order to discourage- mine whether a new drug has any clinical advantage over the being treatments.
Track 12: Pharmaceutical Nanotechnology
Pharmaceutical nanotechnology is the instigative, fleetly arising branch of medical wisdom that deals with employing Nano scale accoutrements as medicine delivery and/ or individual tools. As medicine delivery tools, Nano delivery systems can be used to enhance the point specific, targeted delivery of precise drugs.
Track 13: Bio pharmaceutics
Bio pharmaceutics can be defined as the study of the physical and chemical properties of drugs and their proper dosage as related to the onset, duration, and intensity of medicine action, or it can be defined as the study of the goods of physicochemical properties of the drug and the medicine product, in vitro, on the bioavailability of the medicine, in vivo, to produce a asked remedial effect. Studies in bio pharmaceutics use both in vitro and in vivo methods. In vitro methods are procedures employing test outfit and outfit without involving laboratory animals or humans. In vivo methods are more complex studies involving human subjects or laboratory animals.
Track 14: Ecopharmacovigilance
Environmental scientists have made great strides to regulate pharmaceutical waste. Still, the monitoring of arising environmental problems convinced by medicines should attract the farther interest of drugstore and pharmacovigilance scientists. Ecopharmacovigilance (EPV) as a kind of pharmacovigilance for the atmosphere is extensively honoured as essential to minimize the environmental impact of pharmaceutical poisons. The end of ecopharmacovigilance is to cover the adverse goods of medicinal in the humans through non remedial environmental exposure.
Track 15: Drug development
Medicine development is the process of bringing a new medicine patch into clinical practice. In its broadest description this encompasses all way from the introductory exploration process of chancing a suitable molecular target to supporting the marketable launch of the medicine. New medicines must be developed so that we can continue our chosen cultures and help the misery and death caused by conditions. Disease- causing vectors continue to evolve, throwing up new challenges and in general, humans are living longer so they've further time to be exposed to conditions.
Drug Discovery continuing evolution, involving the organisation of better Drug Discovery services, the development of innovative models of care, and the discovery of new research innovations, drives us to share the latest discoveries for the benefit of all. Many challenges still exist, but by drawing on the successes from the past and moving forward with new knowledge together, we can help shape a better future for professionals and patients alike.
CLINICAL TRAILS-2023 conference will offer the Drug Discovery. Clinical trials, Drug safety, pharmacovigilance, drug developments communities the possibility for educational exchanges, scientific news and best practice updates while protecting the safety, health, and well-being of all congress participants. Drug selection, ethical drugs and molecular therapeutics are broad categories that deal with situations affecting every community. Increasing understanding and Implementing Drug Discovery, Drug evaluations, clinical trials, Drug safety, pharmacovigilance, drug developments, and Reverse pharmacology through prototypes drug and Molecular Medicine are crucial steps towards Drug discovery and development resources It is estimated that over one billion people globally have a diseases, Infectious Pains or substance use suffer from such conditions, placing mental disorders among the leading causes of ill-health and disability worldwide.
Abstract Submission Criteria and Eligibility
Presentation Requirements (GPCTS-2023):
- Participating authors are answerable for registration, travel, and hotel costs. Note: Those with submitted abstracts will get an acknowledgment mail enabling them to enrol for the gathering.
- Abstracts will be compiled, and conference books are made available to participants at the conference (GPCTS-2023).
- Any presenter who is unable to attend should arrange for another qualified individual to present the paper/poster in question. If such a change is necessary, please notify our conference team
- Oral paper introductions will have 30-minute schedule time slot. The keynote session will have for 45-minute presentation duration, workshop/special session will have 1-hour long schedule opening and symposium will have 1-hour long availability followed by 5-minute Q&A session.
- Graduate and master’s understudies are qualified to present their abstracts (GPCTS-2023) under poster and e-poster presentation category.
- Ph.D. understudies are qualified to submit their abstract under special YRF (Young Researcher's Forum), poster and e-poster presentation category.
- NOTE: YRF category includes short oral presentation especially for Ph. D. students
- Extended abstract: Submissions should utilize the Abstract Template. Papers submitted in this category may represent original empirical research, (GPCTS-2023) theoretical development, reviews, or critiques.
Participation Options and Benefits
Participation Options: Clinical Trials Conference provides the participants with different modes or ways to participate such as Delegate or Speaker (GPCTS-2023) under ACADEMIC / STUDENT / BUSINESS Category. Mode of participation is Online through Power Point Presentation/ Video Presentation on Cisco Webinars.
- Keynote speaker: 45-50 minutes
- Speaker (oral presentation): 25-30 minutes (only one person can present)
- Speaker (workshop): 45-50 minutes (more than 1 can present)
- Speaker (special session): 45-50 minutes (more than 1 can present)
- Speaker (symposium): more than 45 minutes (more than 1 can present)
- Delegate (only registration): will have access to all the sessions with all the benefits of registration
- Poster presenter: can present a poster and enjoy the benefits of delegate
- Remote attendance: can participate via video presentation or e-poster presentation
- Exhibitor: can exhibit his/her company’s products by booking exhibitor booths of different sizes
- Media partner
- Sponsor (GPCTS-2023)
Benefits of Joining Conference:
- Get your abstract published with DOI
- Get Certified for your participation
- Reduced Costs Affordability
- Knock Down Geographical Barriers
- Convenience from comfort of your own home or from work
- They’re Archived: Ability to view events in the recording
- Great resource for learning new career skills
- Learn from the Pros
- Global exposure to your research
- Make new connections (GPCTS-2023)
- Significant time saving
- Wider Reach
- Position yourself as the expert
- Get your abstracts published with unique DOI in International Journals
- Get up to 50% discounts for publishing your entire article in our open access International Journals
- Get Handbooks and conference kits (GPCTS-2023)
- Get an access to the network with eminent personalities from worldwide.
Past Conference Report
All accepted abstracts will be published in respective Conference Series International Journals.
Abstracts will be provided with Digital Object Identifier by